Scholarly Research Exchange

Scholarly Research Exchange / 2009 / Article

Clinical Study | Open Access

Volume 2009 |Article ID 123481 |

T. M. Reshetnyak, G. V. Saparin, P. V. Ivannikov, V. I. Reshetnyak, "Corticosteroids and Cholelithiasis in Systemic Lupus Erythematosus", Scholarly Research Exchange, vol. 2009, Article ID 123481, 9 pages, 2009.

Corticosteroids and Cholelithiasis in Systemic Lupus Erythematosus

Received11 Dec 2008
Revised05 Mar 2009
Accepted09 Mar 2009
Published25 Mar 2009


The aim. To evaluate the frequency of gallstone formation and alteration of plasma lipid profiles in SLE patients long treated with prednisolone. Material and methods. Sixty patients with SLE were divided into 2 groups: (1) 38 SLE patients without gallstones; (2) 22 SLE patients with gallstones. Gallbladder ultrasonography was performed in all the patients, and the serum lipid profile was determined. To identify the composition and structure of gallstones obtained during cholecystectomy, color cathodoluminescence scanning electromicroscopy was used. Results. Gallstone disease was detected in 22 (36.7%) patients of the 60 examinees and in 22 (68.8%) of the 32 SLE patients receiving prednisolone therapy; whereas none of the 28 prednisolone-untreated patients was found to have the disease (P=.001). There were the most significant differences between the SLE patients with and without gallstones in the duration of administration of prednisolone and in its mean daily and mean monthly doses, and cumulative ones. Conclusion. Age at the onset of the disease, the mean daily dose of corticosteroids, and the duration of therapy with these agents are the most likely factors predisposing to gallstone disease in SLE patients. The CCL-SEM study identified predominantly the protein-cholesterol structure of gallstones.


  1. H. M. Belmont, S. B. Abramson, and J. T. Lie, “Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Interactions of inflammatory cells and activated endothelium,” Arthritis & Rheumatism, vol. 39, no. 1, pp. 9–22, 1996. View at: Publisher Site | Google Scholar
  2. M. J. Seleznick and J. F. Fries, “Variables associated with decreased survival in systemic lupus erythematosus,” Seminars in Arthritis and Rheumatism, vol. 21, no. 2, pp. 73–80, 1991. View at: Publisher Site | Google Scholar
  3. M. Abu-Shakra, M. B. Urowitz, D. D. Gladman, and J. Gough, “Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death,” Journal of Rheumatology, vol. 22, no. 7, pp. 1259–1264, 1995. View at: Google Scholar
  4. E. F. Borba and E. Bonfá, “Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies,” Lupus, vol. 6, no. 6, pp. 533–539, 1997. View at: Publisher Site | Google Scholar
  5. M. Petri, D. Spence, L. R. Bone, and M. C. Hochberg, “Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices,” Medicine, vol. 71, no. 5, pp. 291–302, 1992. View at: Publisher Site | Google Scholar
  6. E. M. Tan, A. S. Cohen, and J. F. Fries, “The 1982 revised criteria for the classification of systemic lupus erythematosus,” Arthritis & Rheumatism, vol. 25, no. 11, pp. 1271–1277, 1982. View at: Publisher Site | Google Scholar
  7. C. Bombardier, D. D. Gladman, M. B. Urowitz et al., “Derivation of the SLEDAI. A disease activity index for lupus patients,” Arthritis & Rheumatism, vol. 35, no. 6, pp. 630–640, 1992. View at: Publisher Site | Google Scholar
  8. G. Assmann, H. Schriewer, G. Schmitz, and E. O. Hägele, “Quantification of high-density-lipoprotein cholesterol by precipitation with phosphotungstic acid/MgCl2,” Clinical Chemistry, vol. 29, no. 12, pp. 2026–2030, 1983. View at: Google Scholar
  9. W. T. Friedewald, R. I. Levy, and D. S. Fredrickson, “Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge,” Clinical Chemistry, vol. 18, no. 6, pp. 499–502, 1972. View at: Google Scholar
  10. G. V. Saparin, “Cathodoluminescence: new methods in scanning electron microscopy,” in Biophysical Electron Microscopy, pp. 451–478, Academic Press, New York, NY, USA, 1990. View at: Google Scholar
  11. S. K. Obyden, P. V. Ivannikov, and G. V. Saparin, “Color cathodoluminescence display in the scanning electron microscope of deep relief surfaces,” Scanning, vol. 19, no. 8, pp. 533–540, 1997. View at: Publisher Site | Google Scholar
  12. A. S. Loginov, S. M. Chebanov, A. V. Petrakov, G. V. Saparin, S. K. Obyden, and P. V. Ivannikov, “Investigation of cholesterol, bilirubin, and protein distribution in human gallstones by color cathodoluminescence scanning electron microscopy and transmission electron microscopy,” Scanning, vol. 20, no. 1, p. 17, 1998. View at: Google Scholar
  13. V. I. Reshetnyak, Mechanisms of Bile Formation and Primary Biliary Cirrhosis, Red Square, Moscow, Russia, 2003.
  14. W. H. Ettinger, Jr. and W. R. Hazzard, “Elevated apolipoprotein-B levels in corticosteroid-treated patients with systemic lupus erythematosus,” The Journal of Clinical Endocrinology & Metabolism, vol. 67, no. 3, pp. 425–428, 1988. View at: Google Scholar
  15. W. H. Ettinberg, D. Applebaum-Bowden, and W. R. Hazzard, “Post heparin lipases in systemic lupus erythematosus; evidence for defect in triglyceride removal,” Arthritis & Rheumatism, vol. 29, p. 593, 1986. View at: Google Scholar
  16. W. H. Ettinger, H. F. Klinefelter, and P. O. Kwiterovitch, “Effect of short-term, low-dose corticosteroids on plasma lipoprotein lipids,” Atherosclerosis, vol. 63, no. 2-3, pp. 167–172, 1987. View at: Publisher Site | Google Scholar
  17. G. P. van Berge-Henegouwen, N. G. Venneman, P. Portincasa, A. Kosters, K. J. van Erpecum, and A. K. Groen, “Relevance of hereditary defects in lipid transport proteins for the pathogenesis of cholesterol gallstone disease,” Scandinavian Journal of Gastroenterology, vol. 39, no. 1, supplement 241, pp. 60–69, 2004. View at: Publisher Site | Google Scholar
  18. H. H. Wang and D. Q.-H. Wang, “Reduced susceptibility to cholesterol gallstone formation in mice that do not produce apolipoprotein B48 in the intestine,” Hepatology, vol. 42, no. 4, pp. 894–904, 2005. View at: Publisher Site | Google Scholar
  19. K. J. van Erpecum, “Biliary lipids, water and cholesterol gallstones,” Biology of the Cell, vol. 97, no. 11, pp. 815–822, 2005. View at: Publisher Site | Google Scholar
  20. P. Portincasa, A. Moschetta, and G. Palasciano, “From lipid secretion to cholesterol crystallization in bile. Relevance in cholesterol gallstone disease,” Annals of Hepatology, vol. 1, no. 3, pp. 121–128, 2002. View at: Google Scholar
  21. D. Jüngst, E. Gussmann, B. Zündt et al., “Solubility of cholesterol in the crystal-free gallbladder bile of gallstone patients,” Journal of Laboratory and Clinical Medicine, vol. 144, no. 3, pp. 134–140, 2004. View at: Publisher Site | Google Scholar
  22. V. M. Sherbakov and A. V. Tikhonov, Isoforms of Human Liver Cytochrome P450, Press “Souzinformbiology KALINA” VINITI RAS, Moscow, Russia, 1995.
  23. H. H. Wang, N. H. Afdhal, and D. Q.-H. Wang, “Estrogen receptor α, but not β, plays a major role in 17β-estradiol-induced murine cholesterol gallstones,” Gastroenterology, vol. 127, no. 1, pp. 239–249, 2004. View at: Publisher Site | Google Scholar
  24. G. Novacek, “Gender and gallstone disease,” Wiener Medizinische Wochenschrift, vol. 156, no. 19-20, pp. 527–533, 2006. View at: Publisher Site | Google Scholar
  25. K. Chijiiwa, I. Hirota, and H. Noshiro, “High vesicular cholesterol and protein in bile are associated with formation of cholesterol but not pigment gallstones,” Digestive Diseases and Sciences, vol. 38, no. 1, pp. 161–166, 1993. View at: Publisher Site | Google Scholar
  26. S. M. Strasberg, J. L. Toth, S. Gallinger, and P. R. C. Harvey, “High protein and total lipid concentration are associated with reduced metastability of bile in an early stage of cholesterol gallstone formation,” Gastroenterology, vol. 98, no. 3, pp. 739–746, 1990. View at: Google Scholar
  27. H. Zhou, B. Chen, R.-X. Li et al., “Large-scale identification of human biliary proteins from a cholesterol stone patient using a proteomic approach,” Rapid Communications in Mass Spectrometry, vol. 19, no. 23, pp. 3569–3578, 2005. View at: Publisher Site | Google Scholar
  28. M. Wilhelmi, C. Jüngst, M. Mock et al., “Effect of gallbladder mucin on the crystallization of cholesterol in bile,” European Journal of Gastroenterology and Hepatology, vol. 16, no. 12, pp. 1301–1307, 2004. View at: Publisher Site | Google Scholar
  29. L. Finzi, V. Barbu, P.-R. Burgel et al., “MUC5AC, a gel-forming mucin accumulating in gallstone disease, is overproduced via an epidermal growth factor receptor pathway in the human gallbladder,” American Journal of Pathology, vol. 169, no. 6, pp. 2031–2041, 2006. View at: Publisher Site | Google Scholar
  30. B. Sripa, P. Kanla, P. Sinawat, and M. R. Haswell-Elkins, “Opisthorchiasis-associated biliary stones: light and scanning electron microscopic study,” World Journal of Gastroenterology, vol. 10, no. 22, pp. 3318–3321, 2004. View at: Google Scholar
  31. T. Kodaka, T. Sano, K. Nakagawa, J. Kakino, and R. Mori, “Structural and analytical comparison of gallbladder stones collected from a single patient: studies of five cases,” Medical Electron Microscopy, vol. 37, no. 2, pp. 130–140, 2004. View at: Publisher Site | Google Scholar

Copyright © 2009 T. M. Reshetnyak et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.